Leo Pharma ends US partnership
Leo Pharma will no longer market the psoriasis drug Otrexup on the US market – a drug the Danish-based groups paid millions to gain the rights to. The move comes at a time when Leo Pharma is already under a lot of pressure overseas, but it was the Danish group's own decision, it says.
BY BENJAMIN WERNER CHRISTENSEN
Antares Pharma has regained the US rights to the psoriasis drug Otrexup, meaning the partnership with Denmark’s Leo Pharma is off, the company writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Foam product should boost Leo Pharma’s US business
For abonnenter
Leo Pharma enters Japanese alliance
For abonnenter
Leo Pharma unfazed by biological competition
For abonnenter
